Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Psychedelic-assisted therapy

The clinical model pairing a psychedelic session with structured psychological support.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.

Psychedelic-assisted therapy shows promise for conditions like depression, PTSD, anxiety, and alcohol use disorder, with several randomized controlled trials and open-label studies reporting large, rapid, and sometimes durable improvements. However, the evidence base remains limited by small sample sizes, open-label designs, and heterogeneity in protocols, so conclusions about efficacy are preliminary and require confirmation in larger, well-controlled trials.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2017
Supports

Psilocybin with psychological support produced large reductions in depressive symptoms (Cohen's d = 2.2 at week 1, 2.3 at week 5) that remained significant at 6 months (d = 1.4).

open-label trial Sample size: 20

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011
Supports

Psilocybin at 20 and 30 mg/70 kg occasioned mystical-type experiences in 72% of volunteers, with persisting positive changes in attitudes, mood, and behavior at 14 months.

double-blind dose-effect study Sample size: 18

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases 2014
Supports

LSD-assisted psychotherapy significantly reduced trait and state anxiety at 2 months (effect sizes 1.1 and 1.2), with reductions sustained for 12 months.

double-blind, randomized, active placebo-controlled pilot study Sample size: 12

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. 2017
Unclear

This review discusses the therapeutic potential of psychedelic drugs but does not provide specific quantitative findings.

review

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. 2010
Unclear

The abstract does not provide specific results, only the study description.

randomized controlled pilot study

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder 2022
Supports

Two administrations of high-dose psilocybin improved the percentage of heavy drinking days in patients with AUD undergoing psychotherapy compared to active placebo.

double-blind randomized clinical trial

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression 2017
Supports

Patients reported that psilocybin treatment promoted connection and acceptance, in contrast to conventional treatments which reinforced disconnection and avoidance.

qualitative thematic analysis Sample size: 20

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. 2020
Supports

The authors propose that the subjective effects of psychedelics are necessary for their enduring therapeutic benefits, accounting for the majority of benefit.

theoretical review

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects 2014
Supports

LSD-assisted psychotherapy led to sustained reductions in anxiety and improved quality of life at 12 months, with participants reporting insightful, cathartic, and interpersonal experiences.

qualitative content analysis with prospective follow-up Sample size: 10

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. 2018
Unclear

The abstract does not provide specific results, only the study description.

randomised, double-blind, dose-response, phase 2 clinical trial

Increased global integration in the brain after psilocybin therapy for depression. 2022
Unclear

The abstract does not provide specific results, only the study description.

observational

A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) 2012
Mixed

MDMA-assisted psychotherapy did not show statistically significant reductions in clinician-rated CAPS scores (p = 0.066), but did show significant self-reported improvement on the PDS (p = 0.014).

randomized, double-blind, active-placebo controlled pilot study Sample size: 12

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. 2013
Supports

At a mean of 45.4 months follow-up, the majority of subjects maintained statistically and clinically significant gains in PTSD symptom relief from MDMA-assisted psychotherapy.

prospective long-term follow-up study Sample size: 19

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. 2020
Supports

Psychological flexibility fully mediated the effect of mystical and insightful experiences on decreases in depression and anxiety following a psychedelic experience.

cross-sectional survey study Sample size: 985

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. 2019
Supports

MDMA-assisted psychotherapy produced significantly greater reductions in CAPS-IV scores than control (between-group difference -22.0, p < 0.001, Cohen's d = 0.8), with 54.2% of the active group no longer meeting PTSD diagnostic criteria.

pooled analysis of six phase 2 randomized controlled trials Sample size: 103

Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026
Supports

MDMA-assisted therapy significantly reduced trauma symptoms of discrimination by 38% (Cohen's d = 1.28, p = .046), though the sample size was very small.

preliminary study Sample size: 5

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study 2026
Supports

Greater therapeutic gains in ketamine-assisted psychotherapy followed sessions with higher mystical-type experience scores, with the patient attributing improvements to the psychological and spiritual impact.

case study Sample size: 1

Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature 2026
Supports

Most of the 24 included studies reported reduced PTSD symptoms post-intervention, with some noting decreased dissociative symptoms at higher MDMA doses.

descriptive systematic review Sample size: 335

Reframing distress in oncology: the potential of psychedelic-assisted therapy. 2026
Supports

Recent trials in advanced cancer populations report improvements in anxiety, depression, pain-related distress, and quality of life following one or two dosing sessions of psychedelic-assisted therapy.

review

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review 2026
Unclear

This review categorizes psychosocial protocols used in psychedelic research, noting limited reporting and heterogeneity as methodological challenges.

scoping review

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder 2026
Supports

Participants in ketamine-assisted psychotherapy for MAUD described reduced emotional and cognitive reactivity and translation of psychological shifts into behavioral change.

qualitative study embedded in open-label pilot trial Sample size: 14

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects. 2026
Supports

Greater improvement in PTSD symptoms was associated with more psychotherapy sessions (β = 1.03 per session) and more ketamine sessions (β = 1.15 per session), but most included studies were of poor quality.

systematic review and individual participant data meta-analysis Sample size: 533

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review 2026
Unclear

There is considerable variation in music selection and use in psychedelic-assisted psychotherapy trials, with no standardized protocol.

systematic review

Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments 2026
Supports

The strongest direct evidence for psychedelic-assisted therapy in addiction treatment comes from a limited number of randomized and controlled studies, suggesting cautious clinical potential rather than established effectiveness.

narrative review

Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study 2026
Supports

64.3% of participants were willing to participate in a psychedelic therapy trial, with willingness significantly associated with higher expectations of research success.

mixed-method study Sample size: 112

Points of agreement

  • Psychedelic-assisted therapy (with psilocybin, LSD, MDMA, and ketamine) is associated with large, rapid reductions in symptoms of depression, anxiety, and PTSD across multiple studies.
  • Subjective effects (e.g., mystical-type experiences, psychological flexibility) are consistently linked to therapeutic outcomes.
  • Improvements often persist for months to over a year after treatment, as shown in several follow-up studies.
  • The therapy is generally well-tolerated with no serious adverse events reported in the reviewed studies.

Conflicts

  • One pilot study (22029) found no significant clinician-rated improvement on the CAPS despite significant self-reported improvement, suggesting possible divergence between measures.
  • The quality of evidence varies widely, from open-label and qualitative studies to double-blind RCTs, leading to different levels of confidence in findings.

Gaps

  • Most studies have small sample sizes, limiting generalizability and statistical power.
  • There is a lack of large, multi-site phase 3 trials for most substances and conditions, though some are underway.
  • Heterogeneity in treatment protocols (dose, number of sessions, psychotherapy model, music use) makes cross-study comparisons difficult.
  • Long-term durability beyond 12 months is not well-established for most indications.
  • Few studies include diverse populations or examine effects on discrimination-related trauma, with most samples being predominantly white and male.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psychedelic-assisted therapy, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psychedelic-assisted therapy or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

2,711 articles · 1,232 from the last two years · 1,591,803 participants across 803 studies reporting sample size

Common study designs

review 640 qualitative study 110 systematic review 143 randomized controlled trial 85 theoretical or philosophical paper 431

Research

Synthesize the evidence → Search all →

Psychedelic-Assisted Psychotherapy Education at GSPP: Assessing PsyD Student and Alumni Interest, Attitudes, and Perceived Training Needs

July 16, 2026 Devon Seelig

Interest in psychedelic-assisted psychotherapy (PAP) is growing rapidly, yet formal training in PAP within accredited doctoral psychology programs remains nearly absent. A survey of current students and alumni of a PsyD program at the University of Denver found substantial interest in greater exposure to PAP-related education, alongside thoughtful concerns. Results highlighted a perceived gap between the expansion of psychedelic medicine and the current level of formal training available. The project provides program-specific data to inform internal discussions on potential future training directions and may contribute to broader conversations about graduate-level competency development in PAP.

DOI: 10.56902/etdcrp.2026.20 (opens in new tab) Coursework Accreditation Training meteorology Professional development +6

Psychedelic therapy at the end of life: unexplored alternative to assisted suicide in the UK.

The British journal of psychiatry : the journal of mental science July 14, 2026 Ruslan Zinchenko

Conventional suicide and assisted suicide share parallels, but psychedelic therapy can alleviate end-of-life distress and reduce suicidality. Psychedelics should be rescheduled to enable research into their effectiveness as an adjunct to palliative care before assisted suicide is institutionalised in the UK.

DOI: 10.1192/bjp.2026.10729 (opens in new tab) Full text (opens in new tab) Assisted suicide Drug regulation Psychedelic drugs Terminal care

Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder.

Scientific Reports July 11, 2026 Monnica T. Williams, Sonya C. Faber, Jordan Sloshower et al.

A small preliminary study of five diverse individuals found that MDMA-assisted therapy significantly reduced trauma symptoms related to discrimination. Scores on the Trauma Symptoms of Discrimination Scale dropped by an average of 38% after treatment, a large effect. All participants, who had experienced multiple forms of discrimination including gender, racial, and sexual orientation bias, reported marked improvement. The results suggest MDMA-assisted therapy may help alleviate discrimination-related trauma in marginalized populations, though the small sample size calls for cautious interpretation and further research with larger, more diverse groups.

DOI: 10.1038/s41598-026-59333-w (opens in new tab) Full text (opens in new tab) MDMA Discrimination Oppression Trauma

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study

Journal of Psychoactive Drugs July 3, 2026 Miguel Joaquim Soares Teles Couceiro, Victor José da Conceição Teixeira Amorim Rodrigues, Nuno Manuel Correia Torres

In a patient with generalized anxiety disorder and migraines, mystical-type experiences during ketamine-assisted psychotherapy appeared to contribute to therapeutic improvements. After four intramuscular sessions (0.5-0.9 mg/kg), greater gains followed sessions with higher scores on the Hood Mysticism Scale. The patient attributed progress to the psychological and spiritual impact of the experiences, highlighting the importance of the therapeutic relationship and integration process. This case suggests that subjective mystical experiences may play a meaningful role in therapeutic change during ketamine-assisted psychotherapy.

DOI: 10.1080/02791072.2026.2696253 (opens in new tab) Mysticism Anxiety disorder Therapeutic relationship Outcome game theory +5

Practical Considerations for Psychedelic-Assisted Therapy among Social Workers.

Soc Work July 1, 2026

Social workers are increasingly interested in psychedelic-assisted therapy, but face unique practical and ethical challenges. The article outlines key considerations including legal barriers, the need for specialized training, ethical obligations around informed consent and safety, and the importance of addressing systemic inequities in access. It emphasizes that social workers must integrate their profession's core values of social justice and client self-determination into this emerging treatment model. The piece provides guidance on navigating regulatory uncertainty, preparing clients, and ensuring culturally competent care.

DOI: 10.1093/sw/swag020 (opens in new tab)

Reframing distress in oncology: the potential of psychedelic-assisted therapy.

Current opinion in oncology July 1, 2026 Fatima Zohra Moujahid, Olivier Taymans

Psychedelic-assisted therapy (PAT) may offer a new approach to address the multidimensional nature of psychological and existential distress common across the cancer trajectory. PAT combines psychedelic compounds with structured psychotherapeutic support, including preparatory sessions, a supervised dosing experience, and post-session integration. Psychedelics are thought to enhance neuroplasticity and emotional flexibility, potentially supporting sustained psychological change. Recent trials in advanced cancer populations report improvements in anxiety, depression, pain-related distress, and quality of life following one or two dosing sessions. However, current evidence is limited by small and demographically narrow samples, variable treatment protocols, and potential expectancy effects, and implementation faces practical challenges such as training requirements and resource intensity.

DOI: 10.1097/cco.0000000000001242 (opens in new tab) Full text (opens in new tab) Existential distress Psychedelic-assisted therapy Cancer-related distress Psycho-oncology +1

Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature

Therapeutic Advances in Psychopharmacology July 1, 2026 Karthika Kasiviswanathan, Dinuli Nilaweera, M Morando et al.

MDMA-assisted psychotherapy (MDMA-AP) may help treat not only PTSD but also complex PTSD and borderline personality disorder. A systematic review of 24 studies involving 335 participants found that most reported reduced PTSD symptoms after MDMA-AP, with some noting decreased dissociative symptoms at higher doses. Although no studies directly assessed MDMA-AP for complex PTSD or borderline personality disorder, improvements in emotional regulation, interpersonal functioning, identity coherence, and abandonment concerns were reported. Adverse drug reactions were mild to moderate, though specific safety concerns remain. These findings offer preliminary insights for future research and clinical considerations.

DOI: 10.1177/20451253251408626 (opens in new tab) Ecstasy Borderline personality disorder Psycinfo Abandonment legal +11

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review

Journal of Psychopharmacology June 26, 2026 Flavia Giaffone de Paiva Ferreira, João Ariel Bonar Fernandes, Renato Filev et al.

A scoping review categorized psychosocial protocols used in psychedelic research for mental health treatment. Seven categories were defined, reflecting distinct emphases on the substance, participant, research team, and sociocultural context. Although limited reporting and heterogeneity remain methodological challenges, the proposed parameters suggest a shared language to describe, compare, and examine psychosocial protocols across studies, reducing conceptual uncertainty. The review may facilitate research decision-making and support structured, replicable study designs while allowing flexibility for individualized and culturally responsive care. Explicitly defining the intended purpose of psychosocial protocols could improve transparent reporting and evaluation.

DOI: 10.1177/02698811261453850 (opens in new tab) Psychosocial Categorization Observational study Flexibility engineering +15

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

Frontiers in Psychiatry June 24, 2026 Kathryn Fletcher, Nadine Ezard, Krista J. Siefried et al.

People with methamphetamine use disorder who underwent ketamine-assisted psychotherapy described the treatment as a multi-stage process rather than a simple drug effect. Participants reported that ketamine created a temporary state of reduced emotional and cognitive reactivity, which they called 'psychological space,' making them more receptive to psychotherapy. However, behavioral changes—including reduced methamphetamine use—were variable and depended on ongoing therapeutic engagement, personal motivation, and life context. Participants were uncertain whether improvements came from the ketamine, the therapy, or the supportive environment. Acceptability was generally high when treatment occurred in a structured clinical setting.

DOI: 10.3389/fpsyt.2026.1873497 (opens in new tab) Thematic analysis Context archaeology Cognition Qualitative research +8

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects.

Psychotherapy and Psychosomatics June 19, 2026 Judith Rohde, Tyler M Moore, Kathryn Walker et al.

A systematic review and individual participant data meta-analysis of 12 studies (533 participants) found that higher baseline PTSD severity was the most robust predictor of symptom reduction after combined ketamine and psychotherapy. More psychotherapy sessions, more ketamine sessions, and shorter treatment duration were also associated with greater improvement, but these findings are tentative because most studies were of poor quality. The analysis showed that for each additional psychotherapy session, PTSD symptoms improved by an average of 1.03 points on the PCL-5, and for each additional ketamine session, improvement was 1.15 points. The results require confirmation in well-designed prospective trials.

DOI: 10.1159/000553144 (opens in new tab) Full text (opens in new tab)

Clinical trials

All Psychedelic-assisted therapy trials →